Inbrija and Disease progression - a phase IV clinical study of FDA data

Summary:

Disease progression is reported as a side effect among people who take Inbrija (levodopa), especially for people who are male, 60+ old, also take Nourianz, and have Parkinson's disease.

The phase IV clinical study analyzes which people have Disease progression when taking Inbrija. It is created by eHealthMe based on reports of 7,847 people who have side effects when taking Inbrija from the FDA, and is updated regularly.

What is Inbrija?

Inbrija has active ingredients of levodopa. eHealthMe is studying from 7,848 Inbrija users. Check the latest studies of Inbrija.

What is Disease progression?

Disease progression is found to be associated with 1,801 drugs and 2,253 conditions by eHealthMe. Check the latest studies of Disease progression.



On Jul, 13, 2026

7,847 people reported to have side effects when taking Inbrija.
Among them, 61 people (0.78%) have Disease progression.

Could Inbrija cause Disease progression?

Among these 61 people:

What is the gender of people who have Disease progression when taking Inbrija? *

  • female: 36.73 %
  • male: 63.27 %

What is the age of people who have Disease progression when taking Inbrija? *

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 5 %
  • 50-59: 0.0 %
  • 60+: 95 %

What are other drugs people take besides Inbrija? *

  1. Nourianz: 15 people, 24.59%
  2. Sinemet: 12 people, 19.67%
  3. Nuplazid: 11 people, 18.03%
  4. Rytary: 10 people, 16.39%
  5. Gocovri: 7 people, 11.48%
  6. Amantadine: 6 people, 9.84%
  7. Carbidopa And Levodopa: 6 people, 9.84%
  8. Plavix: 4 people, 6.56%
  9. Clonazepam: 4 people, 6.56%
  10. Synthroid: 4 people, 6.56%

What are other side effects people have besides Disease progression? *

  1. Parkinson's Disease: 19 people, 31.15%
  2. Cough: 15 people, 24.59%
  3. Mobility Decreased (ability to move is reduced): 9 people, 14.75%
  4. Tremor (trembling or shaking movements in one or more parts of your body): 8 people, 13.11%
  5. Dyskinesia (abnormality or impairment of voluntary movement): 7 people, 11.48%
  6. Gait Disturbance: 5 people, 8.20%
  7. Withdrawal Syndrome (a discontinuation syndrome is a set of symptoms occurred due to discontinuation of substance): 4 people, 6.56%
  8. Confusional State: 4 people, 6.56%
  9. Device Occlusion: 4 people, 6.56%
  10. Musculoskeletal Stiffness (stiffness of the body's muscles, joints, tendons, ligaments and nerves): 4 people, 6.56%

What are the existing conditions these people have? *

  1. Parkinson's Disease: 57 people, 93.44%
  2. On And Off Phenomenon: 37 people, 60.66%
  3. Glaucoma (increased fluid pressure in the eye with vision loss): 2 people, 3.28%
  4. Stress And Anxiety: 1 person, 1.64%
  5. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 1.64%
  6. Adrenal Insufficiency (a condition in which the adrenal glands do not produce adequate amounts of steroids): 1 person, 1.64%
  7. Blood Pressure Abnormal: 1 person, 1.64%
  8. Cough: 1 person, 1.64%
  9. Delusion (a false belief or opinion): 1 person, 1.64%
  10. Depression: 1 person, 1.64%

* Approximation only. Some reports may have incomplete information.

Do you take Inbrija and have Disease progression?

- Check whether Disease progression is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, long term effects of, and alternative drugs to Inbrija:

Disease progression treatments and more:

How severe was Disease progression and when was it recovered:

Expand to all the drugs that have ingredients of levodopa:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Inbrija:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Disease progression:

Browse all the conditions that are associated with Disease progression:


How the study uses the data?

The study uses data from the FDA. It is based on levodopa (the active ingredients of Inbrija) and Inbrija (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: